Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MINOXIDIL EXTRA STRENGTH (FOR MEN) vs ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Minoxidil is a potassium channel opener that causes direct vasodilation of peripheral arterioles. It increases blood flow to hair follicles and prolongs the anagen (growth) phase of hair follicles.
Pentazocine is a mixed agonist-antagonist opioid analgesic that binds to mu, kappa, and sigma opioid receptors, primarily acting as an agonist at kappa receptors and partial agonist at mu receptors, resulting in analgesic and sedative effects. Acetaminophen (paracetamol) is an analgesic and antipyretic whose mechanism involves inhibition of cyclooxygenase (COX) enzymes, primarily COX-2, in the central nervous system, and possibly activation of descending serotonergic pathways.
Treatment of androgenetic alopecia (male pattern baldness) in men,Off-label: female pattern hair loss, alopecia areata, chemotherapy-induced alopecia, beard enhancement
Moderate to severe pain where an opioid analgesic is appropriate
Topical: 1 m L of 5% solution (50 mg) applied to the scalp twice daily. Maximum daily dose: 2 m L (100 mg).
One tablet (acetaminophen 500 mg / pentazocine hydrochloride 25 mg) orally every 4 hours as needed for pain; maximum daily dose: acetaminophen 4000 mg (8 tablets) and pentazocine hydrochloride 200 mg (8 tablets).
Terminal elimination half-life is approximately 4.2 hours in patients with normal renal function. However, the pharmacodynamic half-life (duration of antihypertensive effect) is about 24 hours, allowing once-daily dosing.
Acetaminophen: 2-3 hours (prolonged in hepatic impairment). Pentazocine: 2-3 hours (terminal), with clinical analgesic effect lasting 3-4 hours.
Primarily metabolized by glucuronidation via UGT1A1 and UGT1A3 enzymes; minor metabolites include minoxidil sulfate, which is active.
Pentazocine is extensively metabolized in the liver via oxidation and glucuronidation; significant first-pass metabolism. Acetaminophen is metabolized primarily in the liver via conjugation with glucuronide and sulfate, and oxidation via CYP2E1, CYP1A2, and CYP3A4 to a toxic metabolite (NAPQI).
Primarily renal (approximately 95% as parent drug and metabolites). Biliary/fecal excretion is minimal (less than 5%).
Acetaminophen: renal (2-4% unchanged, ~85% as glucuronide and sulfate conjugates). Pentazocine: renal (~60% as unchanged and conjugates), biliary/fecal (~20%).
About 20% bound to plasma proteins (primarily albumin).
Acetaminophen: 10-25% (albumin). Pentazocine: 60-70% (albumin and alpha-1 acid glycoprotein).
Approximately 3-4 L/kg, indicating extensive distribution into tissues.
Acetaminophen: 0.9 L/kg. Pentazocine: 5-7 L/kg (extensive tissue distribution).
Oral: Approximately 90% absorbed, but bioavailability is around 50% due to first-pass metabolism. Topical: Systemic absorption is minimal (approximately 1.4-5% of applied dose).
Acetaminophen oral: 60-90%. Pentazocine oral: ~20% (extensive first-pass metabolism). Intramuscular: pentazocine 100%.
No dose adjustment required for topical minoxidil. For oral minoxidil (off-label for hypertension): GFR 10-50 m L/min: reduce dose by 50%; GFR <10 m L/min: use with caution, reduce dose by 75%.
Cr Cl 30-50 m L/min: use with caution; decrease dose interval to every 6 hours if needed. Cr Cl <30 m L/min: restrict pentazocine; consider alternative. Not recommended for patients on dialysis.
No specific guidelines for topical minoxidil. For oral minoxidil: Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce dose by 75%.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce pentazocine dose by 50%; avoid acetaminophen >2 g/day. Child-Pugh Class C: contraindicated due to acetaminophen hepatotoxicity and pentazocine accumulation.
Not recommended for use in children under 18 years for androgenetic alopecia. Safety and efficacy not established.
Not recommended in children <12 years due to lack of safety data. For adolescents ≥12 years, adult dosing may be considered based on weight (≥50 kg).
No specific dose adjustment required for topical use. Monitor for orthostatic hypotension or fluid retention with oral use. Start at lower end of dosing range if using oral minoxidil.
Reduce pentazocine dose by 50% (e.g., one tablet every 6 hours) due to increased risk of CNS depression, confusion, and constipation. Monitor renal function; avoid exceeding 4 g/day acetaminophen.
None
Pentazocine: Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death. Patients should be monitored for respiratory depression and sedation.
Cardiovascular effects: tachycardia, fluid retention, pericardial effusion (rarely) – risk increases with systemic absorption; avoid use in patients with pheochromocytoma or hypertensive crisis,Hypotension: can occur if applied to broken skin or excessive application,Dermatologic: contact dermatitis, scalp irritation, unwanted facial hair growth (hypertrichosis),Cardiac: avoid in patients with known coronary artery disease or arrhythmias
Respiratory depression risk, especially in patients with compromised respiratory function,Potential for opioid dependence, abuse, and misuse,Risk of withdrawal if discontinued abruptly after prolonged use,Pentazocine may cause opioid withdrawal in patients dependent on pure mu agonists,Acetaminophen hepatotoxicity at high doses or with chronic use; risk increased with alcohol consumption or pre-existing liver disease,Central nervous system depression additive with other CNS depressants,Elderly or debilitated patients may have increased sensitivity to effects,May cause hypotension, especially in hypovolemic patients,Serotonin syndrome risk when used with serotonergic drugs,Pentazocine may cause hallucinations, confusion, or other psychotomimetic effects
Hypersensitivity to minoxidil or any component of the formulation,Concurrent use with other topical hair growth products
Hypersensitivity to either component,Severe respiratory depression (e.g., acute asthma, hypercapnia),Acute or severe bronchial asthma,Suspected surgical abdomen (may obscure diagnosis),Monoamine oxidase inhibitor (MAOI) use (current or within 14 days),Severe hepatic impairment or active liver disease (acetaminophen component),Known or suspected gastrointestinal obstruction (including paralytic ileus)
No significant food interactions. Avoid excessive alcohol intake as it may worsen orthostatic hypotension if systemic absorption occurs.
Avoid alcohol consumption due to increased risk of hepatotoxicity from acetaminophen. No specific food interactions; take with food if gastrointestinal upset occurs.
Minoxidil is pregnancy category C. First trimester: Animal studies show fetal abnormalities (skeletal, cardiovascular) at high doses; no adequate human studies. Second/third trimester: Possible fetal hypotension, hypertrichosis, and perinatal complications. Avoid use in pregnant women unless benefit outweighs risk.
Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity in any trimester. Pentazocine: Limited human data; animal studies show no teratogenicity at clinically relevant doses. However, use in third trimester may cause neonatal respiratory depression and withdrawal syndrome. Overall, risk is low but pentazocine should be avoided near term.
Minoxidil is excreted in human milk. M/P ratio not reported. Potential for adverse effects in nursing infant (e.g., hypotension, fluid retention). Use caution; decide based on importance of drug to mother.
Acetaminophen: Excreted in low amounts (M/P ratio ~0.2-0.9); compatible with breastfeeding. Pentazocine: Excreted in breast milk; M/P ratio unknown; may cause CNS effects in infants. Use with caution, especially in neonates or premature infants. Monitor infant for sedation and respiratory depression.
No specific dose adjustment guidelines. Due to increased plasma volume and renal clearance during pregnancy, effectiveness may be reduced; monitor response and adjust dose as needed, but avoid excessive hypotension. Use lowest effective dose.
Acetaminophen: No significant pharmacokinetic changes in pregnancy; standard dosing (max 3-4 g/day) applies. Pentazocine: Clearance may increase due to enhanced hepatic metabolism; dose adjustments not routinely recommended but monitor response. Avoid high doses near term due to risk of neonatal depression.
Minoxidil extra strength (5%) is a topical vasodilator used for androgenetic alopecia. Onset of hair regrowth typically requires 4-6 months of twice-daily application. Initial shedding of telogen hairs may occur in the first 2-6 weeks due to synchronization of hair cycle. Use in patients with cardiovascular disease or those on antihypertensives may theoretically cause systemic effects but is rare at topical doses. Avoid concomitant use with other topical agents that may irritate scalp. Discontinue if no response after 12 months.
Pentazocine is a mixed agonist-antagonist opioid; avoid in opioid-dependent patients due to risk of precipitated withdrawal. Acetaminophen component limits total daily dose to 4 g (or less in hepatic impairment) to prevent hepatotoxicity. Monitor for respiratory depression, especially in elderly or those with COPD. Injection site reactions (e.g., sterile abscesses, fibrosis) common with repeated intramuscular use. May cause dysphoria, hallucinations, or CNS stimulation (unlike typical opioids). Contraindicated in acute porphyria due to porphyrinogenic potential.
Apply 1 m L to dry scalp twice daily, spreading evenly over affected areas.,Wash hands thoroughly after application to avoid unwanted hair growth.,Initial hair shedding is normal and indicates drug is working; do not stop.,Visible results may take 4-6 months; treatment is lifelong to maintain benefits.,Avoid contact with eyes, mouth, and broken skin; if contact occurs, rinse with water.,Do not use more than directed; systemic side effects are rare but include dizziness and rapid heartbeat.
Do not exceed 4 grams of acetaminophen per day from all sources (including OTC medications).,Avoid alcohol while taking this medication; risk of liver damage increases.,This medication may cause dizziness, drowsiness, or hallucinations; avoid driving or operating machinery until effects are known.,Report any signs of allergic reaction (rash, difficulty breathing) or liver issues (yellow skin/eyes, dark urine).,Do not suddenly stop if used long-term; withdrawal symptoms may occur.,If you have opioid dependence, this medication may precipitate withdrawal symptoms.,This medication may cause constipation; maintain fluid and fiber intake.
"Isocarboxazid, a monoamine oxidase inhibitor (MAOI), increases the risk of severe hypotension when combined with minoxidil, a direct-acting vasodilator used for hypertension. The MAOI potentiates the hypotensive effects of minoxidil by inhibiting the metabolism of norepinephrine and other vasoactive amines, leading to exaggerated vasodilation and blood pressure reduction. Clinically, this can result in symptomatic hypotension, dizziness, syncope, and potentially cardiovascular collapse."
"Morphine and minoxidil coadministration can lead to additive hypotensive effects, increasing the risk of severe orthostatic hypotension and syncope. Morphine's vasodilatory properties via histamine release and opioid-induced reduction in sympathetic tone synergize with minoxidil's direct arterial vasodilation, potentially causing a precipitous drop in blood pressure. This interaction is particularly concerning in patients with compromised cardiovascular function or volume depletion, and may necessitate dose adjustments or avoidance."
"Minoxidil, a potent arterial vasodilator used in hypertension and alopecia, can enhance the hypotensive effects of epoprostenol, a prostacyclin analog that directly dilates pulmonary and systemic arteries. The combined vasodilatory action may lead to additive reductions in systemic blood pressure, potentially causing hypotension, dizziness, or syncope, especially during intravenous epoprostenol infusion for pulmonary arterial hypertension. Clinical outcomes may include orthostatic hypotension, reflex tachycardia, and compromised organ perfusion if doses are not adjusted."
"Pentazocine, a mixed opioid agonist-antagonist, may attenuate the central nervous system (CNS) stimulant effects of dextroamphetamine by competitively blocking mu-opioid receptors and potentially altering dopamine release, leading to reduced analgesic efficacy of pentazocine and diminished therapeutic response to dextroamphetamine in treating attention deficit hyperactivity disorder (ADHD) or narcolepsy. This interaction can result in suboptimal pain control and exacerbation of ADHD symptoms, requiring dose adjustments or alternative therapies."
"The concurrent use of ipratropium, an anticholinergic agent, and pentazocine, a mixed opioid agonist-antagonist, may lead to an increased risk of central nervous system (CNS) depression and anticholinergic adverse effects. Pentazocine can enhance the sedative and respiratory depressant effects of ipratropium, while ipratropium may potentiate pentazocine's anticholinergic actions, such as dry mouth, blurred vision, constipation, and urinary retention. Clinically, this interaction can result in excessive sedation, confusion, and impaired cognitive and motor function, particularly in elderly or debilitated patients."
"The combination of pentazocine, a mixed agonist-antagonist opioid, with triazolam, a benzodiazepine, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and psychomotor impairment. This is due to the synergistic effects of both drugs on GABAergic and opioid receptors in the brainstem and cortex. Clinically, this may result in excessive drowsiness, confusion, ataxia, and an elevated risk of falls or respiratory compromise, particularly in elderly or debilitated patients."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MINOXIDIL EXTRA STRENGTH (FOR MEN) vs ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE, answered by our medical review team.
MINOXIDIL EXTRA STRENGTH (FOR MEN) is a Vasodilator / Hair Growth Stimulant that works by Minoxidil is a potassium channel opener that causes direct vasodilation of peripheral arterioles. It increases blood flow to hair follicles and prolongs the anagen (growth) phase of hair follicles.. ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Pentazocine is a mixed agonist-antagonist opioid analgesic that binds to mu, kappa, and sigma opioid receptors, primarily acting as an agonist at kappa receptors and partial agonist at mu receptors, resulting in analgesic and sedative effects. Acetaminophen (paracetamol) is an analgesic and antipyretic whose mechanism involves inhibition of cyclooxygenase (COX) enzymes, primarily COX-2, in the central nervous system, and possibly activation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MINOXIDIL EXTRA STRENGTH (FOR MEN) and ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MINOXIDIL EXTRA STRENGTH (FOR MEN) is: Topical: 1 m L of 5% solution (50 mg) applied to the scalp twice daily. Maximum daily dose: 2 m L (100 mg).. The standard adult dose of ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is: One tablet (acetaminophen 500 mg / pentazocine hydrochloride 25 mg) orally every 4 hours as needed for pain; maximum daily dose: acetaminophen 4000 mg (8 tablets) and pentazocine hydrochloride 200 mg (8 tablets).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MINOXIDIL EXTRA STRENGTH (FOR MEN) and ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MINOXIDIL EXTRA STRENGTH (FOR MEN) is classified as Category A/B. Minoxidil is pregnancy category C. First trimester: Animal studies show fetal abnormalities (skeletal, cardiovascular) at high doses; no adequate human studies. Second/third trimes. ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is classified as Category A/B. Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity in any trimester. Pentazocine: Limited human data; animal studies show no teratogenicity at c. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.